{"id":"da-302168s","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of genital mycotic infections"},{"rate":"null","effect":"Increased risk of urinary tract infections"},{"rate":"null","effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL498283","moleculeType":"Small molecule","molecularWeight":"405.63"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, DA-302168S reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and lowering blood glucose levels. This mechanism is particularly beneficial for patients with type 2 diabetes.","oneSentence":"DA-302168S is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:30:46.513Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT06953063","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Overweight/Obese Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chendu DIAO Pharmaceutical Group CO., LTD.","startDate":"2025-05-15","conditions":"Overweight and Obesity","enrollment":240},{"nctId":"NCT06534346","phase":"PHASE1","title":"The Food Effect on Pharmacokinetics of DA-302168S","status":"COMPLETED","sponsor":"Chendu DIAO Pharmaceutical Group CO., LTD.","startDate":"2024-07-18","conditions":"Overweight and Obesity","enrollment":16},{"nctId":"NCT06541730","phase":"PHASE1","title":"A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects","status":"COMPLETED","sponsor":"Chendu DIAO Pharmaceutical Group CO., LTD.","startDate":"2024-08-30","conditions":"Overweight and Obesity","enrollment":48},{"nctId":"NCT06534320","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Characteristics Evaluation of DA-302168S Tablets","status":"COMPLETED","sponsor":"Chendu DIAO Pharmaceutical Group CO., LTD.","startDate":"2024-04-18","conditions":"Overweight and Obesity","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"DA-302168S","genericName":"DA-302168S","companyName":"Chendu DIAO Pharmaceutical Group CO., LTD.","companyId":"chendu-diao-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DA-302168S is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}